TrialDrug design, development and therapy2026

First-in-Human Phase I Trial of HRS-2129, a Selective Nav1.8 Inhibitor: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects.

Jie Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.